(Updated - August 20, 2024 9:15 AM EDT)

Benchmark analyst Robert Wasserman downgraded AbCellera Biologics (NASDAQ: ABCL) from Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE